BNT111

BIOLOGICAL2 trials

Sponsors

BioNTech SE

Conditions

Melanoma (Stage III and IV)Melanoma Stage IIIMelanoma Stage IVUnresectable Melanoma

Phase 2

A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment

CompletedNCT04526899

BioNTech SEMelanoma Stage III, Melanoma Stage IV, Unresectable Melanoma

Start: 2021-05-19End: 2025-11-24Updated: 2026-01-08

Open-label, randomized Phase II trial with BNT111 and cemiplimab in combination or as single agents in patients with anti-PD 1/PD-L1-refractory/relapsed, unresectable Stage III or IV melanoma

CompletedCTIS2023-509513-36-00

BioNTech SEMelanoma (Stage III and IV)

Start: 2021-03-24End: 2025-11-21Target: 157Updated: 2025-11-05